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Clear understanding of the natural history of HIV-1 disease progression is critical for planning and developing appropriate therapeutic strategies for the HIV-1-infected population and also for allocating healthcare resources [1, 2] . It is widely held that HIV-1 infection might progress faster in individuals in African countries than in individuals in Western countries. It has been argued that this would be related to a higher burden of infectious diseases in Africa, which is known to induce chronic immune activation and thereby provide more viral target cells and accelerated loss of CD4 T cells once the patient becomes infected with HIV-1 [3] . This hyperimmune activation hypothesis is in line with the more-recent insights in AIDS pathogenesis, which show that the level of bystander immune activation induced in the host determines the rate of loss of CD4 T cells and progression to AIDS [4, 5] .
Although the majority of HIV-1 infections occur in sub-Saharan Africa, only very limited information is available about that region. Early studies on disease progression and survival times indeed showed a faster disease progression in individuals in some African countries than in individuals in industrialized countries [6] [7] [8] [9] . Recent reports based on long-term follow-up prospective cohort studies in Uganda, Malawi, and Tanzania indicate that, before the widespread use of anti- unintentional weight loss !10% of body weight, minor mucocutaneous manifestations (e.g., dermatitis, prurigo, fungal nail infections, and angular cheilitis), herpes zoster within the previous 5 years, and recurrent upper respiratory tract infections; clinical stage 3: unintentional weight loss 110% of body weight, chronic diarrhea for 11 month, prolonged fever for 11 month (constant or intermittent), oral candidiasis, oral hairy leukoplakia, pulmonary tuberculosis within the previous year, severe bacterial infections, and vulvovaginal candidiasis; clinical stage 4: HIV-1 wasting syndrome, Pneumocystis carinii pneumonia, toxoplasmosis of the brain, crytosporidiosis with diarrhea for 11 month, isosporiasis with diarrhea for 11 month, cryptococcosis, extrapulmonary cytomegalovirus disease (of an organ other than the liver, spleen, or lymph nodes), herpes simplex virus infection, mucocutaneous progressive multifocal leukoencephalopathy, any disseminated endemic mycosis (e.g., histoplasmosis), candidiasis (of the esophagus, trachea, bronchi, or lungs), atypical mycobacteriosis, disseminated nontyphoid Salmonella septicemia, extrapulmonary tuberculosis, lymphoma, Kaposi sarcoma, and HIV-1 encephalopathy retroviral therapy, HIV-1 infection had a similar natural disease progression in individuals in Africa and in individuals in industrialized nations [10] [11] [12] [13] .
CD4 T cell count is a leading indicator of HIV-1 disease progression in an individual [14, 15] and, together with HIV-1 RNA load, is used as the basis for the initiation and monitoring of therapy [16] . The preseroconversion CD4 T cell count [4] and the rate of decline in CD4 T cell counts after infection are strong predictors of the time to AIDS and death [17, 18] . Information on CD4 T cell counts for individuals at different stages of disease progression, as available for cohorts with prevalent cases of HIV-1 infection, is used to estimate the HIV-1 incubation period and survival time [19] .
Several studies have shown that HIV-1-uninfected Ethiopians have lower CD4 T cell counts than does any other population in Africa or in industrialized countries. The average The median log HIV-1 RNA load for prevalent cases was 3.9 log copies/mL (range, 2.0-6.0 log copies/mL), and that for incident cases was 4.0 log copies/mL (range, 2.0-4.9 log copies/mL). WHO, World Health Organization.
CD4 T cell count in HIV-1-uninfected Ethiopians reportedly ranged from to cells/L [20] [21] [22] [23] [24] [25] . CD4 T cell 6 6 591 ϫ 10 775 ϫ 10 counts ranged from to cells/L elsewhere 6 6 838 ϫ 10 1256 ϫ 10 in Africa and were, for example, cells/L in Dutch 6 1067 ϫ 10 homosexual men [26] [27] [28] [29] [30] . In addition, it has been shown that the level of immune activation in Ethiopians is higher than that in Dutch individuals, even before HIV infection [24] .
Since (1) the extent of immune activation during HIV infection and CD4 T cell counts are the best predictors of disease progression; (2) the level of immune activation in Ethiopians is higher than that in Dutch individuals, even before HIV-1 infection; and (3) Ethiopians start off with significantly lower CD4 T cell counts, one would expect progression of HIV-1 infection in this African population to be faster than that in the Dutch population. Here, we analyze whether the unique immunological profile of healthy Ethiopians results in a shorter survival time after HIV-1 infection in Ethiopian than in Dutch individuals.
PATIENTS AND METHODS
Study population. The data used originated from a cohort study of HIV-1 infection and disease progression in workers from 2 factories in Ethiopia. Cohort study procedures have been described in detail elsewhere [31] . The Ethiopian Health and Nutrition Research Institute Ethics Committee and the National Ethical Clearance Committee approved the study protocol. The cohort enrolled both HIV-1-uninfected and HIV-1-infected factory workers between April 1997 and December 2001, for whom follow-up visits were scheduled every 6 months. Data on followup until June 2002 were used for the present study. During this period, antiretroviral therapy was not available to the Ethiopian cohort participants. We compared the rate of decline in CD4 T cell counts for 149 HIV-1-infected Ethiopians with that for 306 HIV-1-infected Dutch homosexual men and 181 HIV-1-infected Dutch drug users between 1990 and 1995 (i.e., before highly active antiretroviral therapy [HAART] was available in The Netherlands). The Dutch individuals were participants in the ongoing Amsterdam cohort studies [19, 32] . Follow-up visits were scheduled every 3 and 4 months for Dutch homosexual men and drug users, respectively.
Clinical examination. Clinical information on participants in the Ethiopian cohort was obtained through a medical examination that focused on the conditions included in the World Health Organization (WHO) staging system [33] . The staging system includes a clinical axis made up of 32 conditions divided into 4 stages (stage 4 being equivalent to AIDS).
Most diagnoses in our cohort were presumptive, because of our limited access to laboratory investigations. As a result, very few HIV-1-infected individuals in the cohort presented with an AIDS-defining illness during follow-up. Within a few days or weeks, individuals died from conditions presumably related to HIV-1 infection. Of the 29 deaths included in this analysis, 14 were attributable to tuberculosis, 8 were attributable to wasting syndrome, 3 were attributable to pneumonia, and 4 were attributable to unknown causes.
Laboratory analyses. For Ethiopians, HIV-1 screening was performed by use of HIVSPOT (Genelabs Diagnostics) and ELISA (Vironostika HIV-1 Uni-Form II; Organon Teknika) kits. All positive or discrepant results were confirmed by use of a Western blot assay (HIV-1 BLOT 2.2; Genelabs Diagnostics). The absolute number of leukocytes per microliter of whole Lymphocyte subsets were determined by flow cytometry with a FACScan. Assessment of HIV-1 RNA load in plasma was performed on 100-mL samples by use of nucleic acid-based amplification assays: for Ethiopian samples, the Nuclisens assay was used, and, for Dutch samples, the NASBA assay was used. The detection threshold for the Nuclisens assay is 80 copies/ mL, and that for the NASBA assay is 1000 copies/mL. In analyses (see next subsection), all negative samples were given a value of 100 copies/mL. Analyses were repeated by use of a higher number of copies per milliliter for negative samples (1000 copies/mL), but results were similar. Values above the detection limits of the 2 assays were comparable [25] . Results are presented as log 10 RNA copies per milliliter of plasma. Statistical analysis. A continuous-time Markov model with constant transition rates was used to model HIV-1 disease progression, as has been suggested in previous studies [15, 19] . A Markov model was used because it can easily account for the doubly censored data that characterize a cohort with prevalent cases of HIV-1 infection; it can also be constructed to allow for the possibility of death before diagnosis of AIDS [19] . Markov models have been used in various populations to estimate survival times and have been shown to yield results comparable to those obtained from Kaplan-Meier analyses [32, 34] . A general description of the model is shown in figure 1 . We used 4 different approaches and data sets to define stages of disease progression in the model. First, we defined 4 stages of HIV-1 disease progression on the basis of raw absolute CD4 T cell counts (model 1). Second, the same was done with smoothed CD4 T cell counts (model 2). CD4 T cell counts are often characterized by both measurement error and short time-scale variability [15, 34] . Therefore, CD4 T cell counts for each individual were smoothed by use of a kernel smoother (a bandwidth of 1.1 year) applied to the log-transformed data, to determine the disease stage for each individual at each visit [19, 32] . The third model was based on WHO clinical staging for HIV-1 infection and disease (model 3) [33] . Since very few individuals received diagnoses of AIDS during follow-up, we collapsed WHO stages 3 and 4 into 1 stage, to represent the late symptomatic stage in HIV-1 infection. In the fourth model (model 4), a hidden Markov model was used to account for misspecification of CD4 T cell counts [35] . In all the models, the last stage corresponded to death. For those who died later than 1 year after their last visit ( ), information after n p 6 this year was not included. The models allowed bidirectional transitions between adjacent stages, except for death, which is an absorbing stage. Direct progression from any stage to death was allowed, to account for death before a diagnosis of AIDS. As a result, models 1, 2, and 4 were specified by 10 transition rates (l ij ) (figure 1A), and model 3 was specified by 7 transition rates (figure 1B). The transition rates represented the instantaneous hazard of moving between stages. Maximum-likelihood estimates, which accounted for the interval-censored nature of the transition times, were obtained by use of the program MKVPCI 1.0 (available at: http://www.isped.u-bordeaux2 .fr/RECHERCHE/BIOSTATS/Telechargement/MKVPCI/US -Biostats-MKVPCI.htm), for models 1-3, and model 4 was fitted with the msm library in R [36] . For the analysis of decline in CD4 T cell counts, a random-effects model was used. We allowed the rate of decline in CD4 T cell counts to differ by CD4 T cell count category. An individual's CD4 T cell count category was determined by his/her "true" CD4 T cell count, with measurement error and short-time variation eliminated. We used fitted CD4 T cell counts, as obtained by use of a model with random intercept and an integrated Ornstein-Uhlenbeck serial process [37] . In the model, we allowed the slope to change when an individual's fitted CD4 T cell count entered a new CD4 T cell count category. The potential role played by HIV-1 RNA load in decline in CD4 T cell count was assessed by including the HIV-1 RNA load as a cofactor, which was allowed to influence both the intercept and the slope of the decline in CD4 T cell count.
RESULTS
Characteristics of the study population at enrollment. The present study included 149 HIV-1-infected Ethiopians, of whom 132 were prevalent cases and 17 were incident cases (table 1) . They completed a total of 791 visits, with a median of 5 visits/ individual (interquartile range [IQR], 2-8 visits/individual) and a median of 3 years (IQR, 2.0-4.6 years) of follow-up. The median time between 2 successive visits was 6.3 months (IQR, 6.1-6.9 months).
A total of 35 deaths until June 2002 were documented, of which 6 occurred 11 year after an individual's last visit; these individuals were censored at the last visit. The incidence of death was 6.7 deaths/100 person-years. The median time between the last visit and death was 5.2 months (IQR, 3.9-8.2 months). Most of the deaths ( [82.8%]) occurred after n p 24 the individuals were seen at CD4 stage 4 (figure 1A), and 4 individuals (13.8%) died after being seen at CD4 stage 3. Only 1 individual died after being seen at CD4 stage 2, and nobody died after being seen at CD4 stage 1. The median time from the last follow-up visit to death was 4.4 months (IQR, 2.0-7.6 months) for Dutch drug users and 2.6 months (IQR, 1.3-5.1 months) for Dutch homosexual men. The median CD4 T cell count at the last visit before death was cells/L; that 2.8-6.0), and 6.0 (IQR, 5.1-6.0) years for these 3 populations, respectively. The median duration of follow-up until death was 2.1 years (IQR, 1.2-3.4 years) for Ethiopians, 2.9 years (IQR, 1.4-4.5 years) for Dutch drug users, and 3.3 years (IQR, 2.1-4.6 years) for Dutch homosexual men.
We compared the survival times and the decline in CD4 T cell counts for HIV-1-infected Ethiopians with those for 306 HIV-1-infected Dutch homosexual men and 181 HIV-1-infected Dutch drug users, of whom 33 and 37 were incident cases, respectively, and who participated in the Amsterdam cohort studies. At enrollment in our study population, the 3 cohorts had similar age distributions (mean ages, 34.0, 35.1, and 32.3 years for Ethiopians, Dutch homosexual men, and Dutch drug users, respectively), but they showed differences in CD4 T cell counts, CD4 T cell percentages, CD4:CD8 T cell ratios, and HIV-1 RNA loads. The median CD4 T cell count for Ethiopians ( cells/L) was lower than that for Dutch 6 333 ϫ 10 drug users ( cells/L) but was similar to that for Dutch 6 480 ϫ 10 homosexual men ( cells/L). Also, the CD4 T cell per-6 370 ϫ 10 centage was lower for Ethiopians (20%) than for Dutch drug users (32%) and Dutch homosexual men (28%), as was the CD4:CD8 T cell ratio, which was 30% for Ethiopians, 63% for Dutch drug users, and 50% for Dutch homosexual men. The median log 10 HIV-1 RNA load was lower for Ethiopians (4.0 log copies/mL) than for Dutch drug users (4.5 log copies/mL) and Dutch homosexual men (4.4 log copies/mL).
Survival time.
Using the maximum-likelihood approach, we obtained estimates of the transition rates of moving between adjacent HIV-1 disease progression stages (table 2). We then estimated the survival probability distribution functions for the 4 different models (figure 2). The shortest estimated median time from seroconversion to death was 9. Decline in CD4 T cell counts in Ethiopian versus Dutch HIV-1-infected individuals. In both Ethiopian and Dutch HIV-1-infected individuals, the rate of loss of CD4 T cells was strongly dependent on the CD4 T cell count. The higher the CD4 T cell count, the more rapid the loss of CD4 T cells. Since Ethiopians had lower baseline CD4 T cell counts, they thus lost their cells more slowly than did Dutch HIV-1-infected individuals. However, even when Dutch and Ethiopian individuals with similar CD4 T cell counts were compared, the annual loss of CD4 T cells was larger in the Dutch individuals ( figure 3 ). For example, at a CD4 T cell count of 333 cells/L (the median Figure 4 . Rate of decline in CD4 T cell counts in 149 HIV-1-infected Ethiopians, 306 Dutch homosexual men, and 181 Dutch drug users, according to overall range and to different categories of CD4 T cell counts. For the analysis of decline in CD4 T cell counts, a random-effects model was used, allowing the rate of decline in CD4 T cell counts to differ by CD4 T cell count category. An individual's category was determined by his/her "true" CD4 T cell count, with measurement error and short-time variation eliminated. Fitted CD4 T cell count values were obtained by use of a model with a random intercept and an integrated Ornstein-Uhlenbeck serial process. In the model, the slope could change when an individual's fitted CD4 T cell count entered a new CD4 T cell count category. nsi, non-syncytium inducing.
baseline value at which the Ethiopians had their first seropositive visit), the annual loss for Ethiopians was cells/L, 6 32 ϫ 10 whereas it was cells/L and cells/L for Dutch 6 6 68 ϫ 10 79 ϫ 10 homosexual men and drug users, respectively. When the decline in CD4 T cell counts was compared by CD4 T cell count category (figure 4), the overall rate of decline in CD4 T cell counts for Ethiopians appeared to be significantly lower than that for Dutch homosexual men and drug users, in all CD4 T cell categories (all ). Conversely, Dutch homosexual men and drug users P ! .01 had similar rates of decline in CD4 T cell counts, except for the last category ( cells/L), in which Dutch homosexual 6 0-200 ϫ 10 men had a somewhat faster decline, although the difference was not statistically significant ( ). P p .088 Since none of the HIV-1-infected Ethiopians developed infection with SI/X4 HIV-1 strains, we tested whether the more rapid decline in CD4 T cell counts in the Dutch individuals could be attributed to the fraction of Dutch individuals who developed infection with SI/X4 HIV-1 (i.e., 38% of the Dutch homosexual men and 14% of the Dutch drug users) by omitting them in the analyses after SI/X4 HIV-1 strains developed. Although those Dutch homosexual men and drug users who had no evidence of SI/X4 strains had a slower decline in CD4 T cell counts than did those who developed infection with SI/X4 HIV-1 strains (figure 4), they still had a significantly higher rate of decline in CD4 T cell counts than did Ethiopians ( ). We also examined whether the differences in HIV-1 P ! .05 RNA load between Ethiopians and Dutch individuals could explain the differences in decline in CD4 T cell counts, by incorporating HIV-1 RNA load in the model as a cofactor. Although the differences in the slopes of decline in CD4 T cell counts decreased, Ethiopians still had a significantly slower loss of CD4 T cells than did Dutch homosexual men and drug users, independent of the HIV-1 RNA load and even if only Dutch individuals who had no evidence of infection with SI/ X4 HIV-1 strains were considered.
DISCUSSION
For Ethiopian factory workers, the median survival time from HIV-1 seroconversion (range, 9.1-13.7 years) was not shorter than that for individuals in industrialized countries before the introduction of HAART (range, 8-13 years) [2, 19, [38] [39] [40] . Considering the unique immunological profile (i.e., lower CD4 T cell counts) of Ethiopians, this finding is remarkable. We used both clinical markers and CD4 T cell counts to define stages of disease progression in Ethiopians, since these have previously been shown to be independent predictors of death in the same study population [41] . This also allowed us to make comparisons with previous studies in other populations that used either clinical data [42, 43] or CD4 T cell counts [15, 19, 32] to estimate HIV-1 incubation period and survival time.
In the present study, the median survival time varied depending on the data used, but, interestingly, even the shortest survival time estimate in Ethiopians, by use of clinical staging, was within the range of previous estimates from other countries.
We analyzed why survival times were not shorter in Ethiopians despite their low baseline CD4 T cell counts. Ethiopians turned out to lose their CD4 T cells at least twice as slowly as the Dutch individuals, even when Ethiopian and Dutch individuals with similar CD4 T cell counts were compared. The annual loss in CD4 T cells in individuals in industrialized countries before the widespread use of antiretroviral therapy has been estimated to be cells/L [44, 45] . A pos- 6 6 40 ϫ 10 -80 ϫ 10 sible cause for the slower decline in CD4 T cell counts could be the lack of SI/CXCR4-using HIV-1 strains in HIV-1 subtype C (HIV-C)-infected Ethiopians [46] . Although this indeed partially accounted for the observed differences, a slower decline in CD4 T cell counts in Ethiopians was still apparent when they were compared with only those participants in the Amsterdam cohorts who were infected with only non-SI/R5 strains. The HIV-1 RNA load is known to correlate with the rate of loss of CD4 T cells. Moreover, the slower decline in CD4 T cell counts in HIV-1-infected Ethiopians could not be explained by their lower HIV-1 RNA loads, compared with those of Dutch homosexual men and drug users. Notably, the slower loss of CD4 T cells in HIV-C-infected Ethiopians has remarkable similarity with the slower loss of CD4 T cells in HIV-2 infection, which may provide some leads to investigate possible reasons for a slower loss.
Interestingly, similar to the present study, 3 other recent African studies with at least 10 years of follow-up data from Uganda, Malawi, and Tanzania did not demonstrate a shorter survival time [10, 11, 13] . These findings seem difficult to reconcile with the hyperimmune activation hypothesis. It may be that, compared with people in the Western world, Ethiopians and people living in the developing world in general have been strongly selected for the ability to survive despite chronic immune activation because of the high burden of infectious diseases. Studies have shown that, with aging, there is gradual erosion of the naive T cell pool, which is likely the effect of exposure to foreign antigens and decreasing renewal [47] . To survive longer with frequent infectious diseases, one has to have an efficient immune response but should at the same time minimize the accelerated aging of the immune system by curtailing bystander responses. In developing countries, there may have been a strong selection for that low immune activation-related phenotype over many centuries. Notably, it is exactly this phenotype that has been shown to be associated with slow progression of HIV-1 infection in cohorts in the Western world [4, 48] .
Through their participation in the cohort study, the participants had access to free treatment for their general health problems and for some of the opportunistic infections they might have had during the course of HIV-1 infection. Such a standard of care was not available for the general HIV-1-infected population in the country. Therefore, one may expect better survival with HIV-1 infection in these factory workers than in the general HIV-1-infected Ethiopian population. In Uganda, no difference in survival time was found between participants of a population cohort study who received intensive treatment with standard drugs from the WHO essential drug list and those with no such access [11] . If conditions are comparable with this population, our finding may well be representative of survival in the general HIV-1-infected population of Ethiopia. Participants were factory workers, implying that they were all healthy enough to perform their duties in the factories when enrolled into the study, and most were still actively working. Indeed, the majority of prevalent cases of HIV-1 infection were asymptomatic. Thus, there might have been a preselection of healthy individuals for the present study. Note that in developed countries, no difference has been found in HIV-1 incubation time and decline in CD4 T cell counts between homosexual men and injection drug users, even though the latter group has a worse general health status. Hence, there is no reason to assume that preselection, if at all present, could have significantly influenced our results. Although individuals who were too sick to work in the factory (and who potentially had low CD4 T cell counts) could still continue participating in the cohort, we checked whether selective study dropout dependent on CD4 T cell counts occurred and influenced our results on differences in decline in CD4 T cell counts. In a Cox regression analysis with dropout as the end point, the relative risk for dropout at CD4 T cell counts between 200 and 350 cells/L was 1.4 ( ), that for dropout at CD4 T cell counts between 350 P p .49 and 500 cells/L was 1.3 ( ), and that for dropout at CD4 P p .56 T cell counts between 500 and 2000 cells/L was 0.2 ( ), P p .15 compared with dropout at CD4 T cell counts !200 cells/L. Overall, no statistically significant effect of CD4 T cell counts was noted ( ), indicating that the slower decline in CD4 T cell P p .11 counts in Ethiopians was not significantly biased by study dropout. Moreover, since we do know whether the individuals were still alive after loss to follow-up, a model for development of CD4 T cell counts that corrects for informative dropout due to death was fitted, and results did not change.
In conclusion, survival time in HIV-1-infected Ethiopians is similar to survival time in individuals from industrialized countries before the widespread use of antiretroviral therapy. The generally low baseline CD4 T cell counts and high levels of immune activation in healthy Ethiopians do not lead to shorter HIV-1 survival times, because individuals with HIV from Ethi-opia lose their CD4 T cells at a slower pace than do individuals with HIV from Western countries.
